40.03
-0.01(-0.02%)
Currency In USD
| Previous Close | 40.04 |
| Open | 38.45 |
| Day High | 40.69 |
| Day Low | 37.06 |
| 52-Week High | 62.4 |
| 52-Week Low | 29.17 |
| Volume | 2.97M |
| Average Volume | 1.96M |
| Market Cap | 7.46B |
| PE | -9.98 |
| EPS | -4.01 |
| Moving Average 50 Days | 39.37 |
| Moving Average 200 Days | 43.41 |
| Change | -0.01 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $1,385.12 as of June 25, 2025 at a share price of $40.03. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 3 years ago, it would be worth $2,163.78 as of June 25, 2025 at a share price of $40.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
GlobeNewswire Inc.
Yesterday at 11:00 AM GMT
Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debtCompany moving forward with independent global commercialization strategy to prioritize patient re
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
GlobeNewswire Inc.
Jun 23, 2025 1:00 PM GMT
Breakthrough Therapy Designation based on promising early clinical evidence observed with daraxonrasib in patients with pancreatic ductal adenocarcinoma (PDAC) RASolute 302, a Phase 3 registrational study of daraxonrasib in patients with previously t
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
GlobeNewswire Inc.
May 14, 2025 12:00 PM GMT
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has bee